patient-derived models acquired resistance can identify effective drug combinations cancer 
targeted cancer therapies produced substantial clinical responses tumors develop resistance drugs describe pharmacogenomic platform facilitates rapid discovery drug combinations can overcome resistance established cell culture models derived biopsy samples lung cancer patients whose disease progressed treatment epidermal growth factor receptor egfr anaplastic lymphoma kinase alk tyrosine kinase inhibitors subjected cells genetic analyses pharmacological screen multiple effective drug combinations identified example combination alk mapk kinase mek inhibitors active alk-positive resistant tumor developed map2k1 activating mutation combination egfr fibroblast growth factor receptor fgfr inhibitors active egfr mutant resistant cancer mutation fgfr3 combined alk src pp60c-src inhibition effective several alk-driven patient-derived models result predicted genetic analysis alone refinements strategy help direct therapeutic choices individual patients 
